Inventor · disambiguated record
Herbert Rudolf Treutlein
Also filed as: TREUTLEIN HERBERT · TREUTLEIN HERBERT RUDOLF
8 granted patents·4 pending applications·36 citations·filing 1997–2021
83Inventor score
Files withKOENTGEN FRANK3Cardio Therapeutics Pty Ltd2AMRAD OPERATIONS PTY LTD1CYTOPIA RES PTY LTD1FRANK KOENTGEN1
Top patents by PatentIndex Score
12 records- 0176US8329737B2Benzimidazoles as selective kinase inhibitorsSTYLES MICHELLE LEANNE·Filed 2010·Granted Dec 11, 2012·6 cites·4 claims
- 0260US11897868B2Heterocyclic inhibitors of PCSK9Cardio Therapeutics Pty Ltd·Filed 2021·Granted Feb 13, 2024·0 cites·17 claims
- 0356US6043069ACatalytic antibodies and a method of producing sameAMRAD OPERATIONS PTY LTD·Filed 1997·Granted Mar 28, 2000·12 cites·3 claims
- 0456US2009269355A1Catalytic antibodies and a method of producing sameKOENTGEN FRANK·Filed 2007·Application pending·0 cites
- 0554US6521741B1Catalytic antibodies and a method of producing sameFRANK KOENTGEN·Filed 2000·Granted Feb 18, 2003·1 cites·20 claims
- 0653US2003148484A1Catalytic antibodies and a method of producing sameFiled 2003·Application pending·0 cites
- 0748US6941229B1Method of designing agonists and antagonists to EGF receptor familyLUDWIG INST CANCER RES·Filed 1999·Granted Sep 6, 2005·11 cites·12 claims
- 0847US2008207613A1Selective Kinase InhibitorsCYTOPIA RES PTY LTD·Filed 2005·Application pending·0 cites
- 0946US6590080B1Catalytic antibodies and a method of producing sameKOENTGEN FRANK·Filed 1998·Granted Jul 8, 2003·5 cites·9 claims
- 1045US11091466B2Heterocyclic inhibitors of PCSK9Cardio Therapeutics Pty Ltd·Filed 2018·Granted Aug 17, 2021·0 cites·18 claims
- 1138US2017166555A1Functionalised and substituted indoles as anti-cancer agentsNovogen ltd·Filed 2014·Application pending·0 cites
- 1230US6326179B1Catalytic antibodies and a method of producing sameKOENTGEN FRANK·Filed 1998·Granted Dec 4, 2001·1 cites·30 claims
Join the waitlist — get patent alerts
Get an alert when Herbert Rudolf Treutlein files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →